April 2, 2014
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of
as Vice President and Global Product Team Lead (GPTL), for PEGPH20 and Oncology. With over 20 years of experience in the biopharmaceutical industry, Mr. Joshi brings strong expertise in oncology drug development and commercialization. Mr. Joshi most recently served as Head of New Product Strategy and Commercial Assessment at Onyx Pharmaceuticals where he co‐led the activities to identify, value and acquire new oncology assets for Onyx. In addition,
has been named Vice President,
Sales & Marketing and will assume leadership of the current sales and marketing efforts for
in addition to continuing to lead the team involved in preparing for the potential approval and subsequent launch of
for use in the pretreatment of the insulin infusion site for people with type 1 diabetes using insulin pumps.
Prior to joining Onyx, Mr. Joshi held roles of increasing responsibility in global marketing, U.S. brand marketing and sales at Bristol Myers Squibb. Most recently Mr. Joshi served as Oncology Business Unit leader for the Intercontinental Region, responsible for product launches and commercialization of oncology products including Erbitux
, and Yervoy
across multiple solid tumors (colorectal cancer, head and neck cancer, melanoma and breast cancer) and Sprycel
in chronic myelogenous leukemia, and
positive, acute lymphoblastic leukemia.
Mr. Daly joined Halozyme in
as Executive Director,
Marketing. Prior to Halozyme, Mr. Daly worked at Amylin for six years in increasingly senior roles in endocrinology marketing for products including Byetta
. Mr. Daly is replacing
, Halozyme's Chief Commercial Officer who resigned effective
March 31, 2014
, to spend more time with his family on the east coast. Mr. Shaffer will continue working with the company as a consultant during a transition period.
"I'm very excited to have
, with his deep oncology experience, leading our PEGPH20 development efforts," said Dr.
, President and Chief Executive Officer. "Through working with Sunil at Onyx, I am confident that he will be a strong and impactful leader for our oncology program. In addition, with the appointment of Steve, we will benefit from having a strong leader and experienced diabetes marketer shaping our commercialization efforts. I would also like to thank Jim for his dedication and significant contributions to the growth and success of Halozyme over the past two and a half years."
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company markets
recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer and
. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at
and follow us on Twitter
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the development and commercialization of our product candidates) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on
February 28, 2014
Schond GreenwayHalozyme Therapeutics858-704-8352
SOURCE Halozyme Therapeutics, Inc.